Genmab nears deal to acquire Dutch cancer drugmaker Merus, Bloomberg News reports
28/09/2025 23:25
Sept 28 (Reuters) - Denmark’s Genmab GMAB.CO is in advanced talks to acquire Merus NV 2GH.F, a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, Bloomberg News reported on Sunday. (Reporting by Rajveer Singh Pardesi in Bengaluru; Editing by Leslie Adler) ((RajveerSingh.Pardesi@thomsonreuters.com;))
Recent news on Merus NV
See all newsNASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab